Monoclonal antibodies anti-IGF1R are used for the therapy of different tumors.18 Early studies justify the investigation of IGF1R as a target for cancer therapy, however, a phase-III study with an anti-IGF1R antibody combined with erlotinib in advanced non-small-cell lung cancer was terminated recently for safety reasons and lack of efficiency (ClinicalTrials.gov Identifier: NCT00673049). Here, IGF1R is linked to non-small cell lung carcinoma.